Biopharma PEG Scientific Inc.

Biopharma PEG Scientific Inc. Biopharma PEG Scientific Inc.

is a biotechnology-oriented company dedicated to manufacturing high purity polyethylene glycol (PEG) derivatives,monodisperse PEGs,click chemisty PEG tools,fluorescent labeling PEGs for academic and commercial use.

🦃 Happy Thanksgiving from Biopharma PEG 🧡As Thanksgiving arrives, we just want to say a genuine thank you.Thank you for ...
11/24/2025

🦃 Happy Thanksgiving from Biopharma PEG 🧡

As Thanksgiving arrives, we just want to say a genuine thank you.
Thank you for your trust, your projects, and the chance to grow together this year.

To support your work through the holiday season, our PEGs are:
✅ High purity (>95%) with low impurities
✅ Available from gram to kilogram scale
✅ Offered at a fair, competitive price

If you’re planning your next order or scaling up, we’re here to help make things a little easier.

👉 Learn more: http://www.biochempeg.com/
📩 Email us anytime at sales@biochempeg.com

Wishing you a warm, restful, and happy from all of us at Biopharma PEG. 🧡

💡 AI + Nanomedicine: Unlocking Brain-Targeted mRNA DeliveryA groundbreaking study in ACS Nano presents an AI-validated f...
09/25/2025

💡 AI + Nanomedicine: Unlocking Brain-Targeted mRNA Delivery
A groundbreaking study in ACS Nano presents an AI-validated framework for engineering brain-targeted lipid nanoparticles (BT-LNPs), designed to cross the blood–brain barrier (BBB) and achieve selective neuronal transfection.

🔬 How it works:
The team created a library of BT-LNPs formulated with:
● SM-102 (ionizable lipid, also used in COVID-19 vaccines)
● DOPE & cholesterol
● PEG-lipids (DMG-PEG1000 and DMG-PEG2000)
👉 Importantly, DMG-PEG2000 was conjugated to small molecules (e.g., acetylcholine, glucose, ni****ne), enabling receptor interactions for BBB crossing.
👉 To balance stability and cellular uptake, shorter PEG chains like DMG-PEG1000 were included, reducing steric hindrance and enhancing targeting efficiency.

✨ Key Outcomes:
🟩 Acetylcholine-modified LNPs showed a 3.6-fold increase in brain transfection vs. untargeted LNPs.
🟩 Human iPSC-derived BBB and brain organoid models confirmed successful neuron transfection.
🟩 AI-based predictions aligned with in vivo results, accelerating discovery and reducing animal testing.

This work highlights a scalable, modular platform for precision CNS gene therapies, with enormous potential for treating neurodegenerative diseases.

😄 We are proud that DMG-PEG1000 and DMG-PEG2000, essential PEG-lipids for LNP formulation, are available from Biopharma PEG.

🔗 Learn more: https://www.biochempeg.com/product/mPEG-DMG.html

📖 Full article: https://doi.org/10.1021/acsnano.4c15013

🚀 ADC Market & Pipeline Update – H1 2025Antibody-drug conjugates (ADCs) remain one of the fastest-growing areas in oncol...
09/22/2025

🚀 ADC Market & Pipeline Update – H1 2025
Antibody-drug conjugates (ADCs) remain one of the fastest-growing areas in oncology.
🔹 As of today, 19 ADCs are approved worldwide.
🔹 In H1 2025, global ADC sales reached ~$8B, with full-year sales expected to surpass $16B.
🔹 Leading products like Enhertu, Padcev, Kadcyla, Polivy, Adcetris, and Trodelvy all reported strong performances.

At the same time, innovation in the pipeline continues:
🔹 200+ clinical-stage ADCs globally, targeting 50+ antigens
🔹 41 ADCs in Phase III, including emerging targets such as HER3, B7-H3, CLDN18.2, ROR1
🔹 Bispecific ADCs (e.g., EGFR/HER3, CD3/CD7) entering late-stage trials
🔹 Expansion into rare cancers, refractory tumors, and even non-oncology diseases
🔹 Ongoing payload and linker innovation, including DXd-based payloads and peptide linkers

👉 Read our full article for a deep dive into H1 2025 ADC sales performance and the Phase III pipeline shaping the future of targeted therapies: https://www.biochempeg.com/article/447.html

💡 Biomimetic Nanoparticles to Combat Intracellular BacteriaResearchers at Kumamoto University developed silver-loaded po...
09/16/2025

💡 Biomimetic Nanoparticles to Combat Intracellular Bacteria

Researchers at Kumamoto University developed silver-loaded poly(lactic-co-glycolic) nanoparticles (Ag-P NPs), surface-modified with polyethyleneimine (Ag-PP NPs) and fused with Salmonella Typhimurium membrane vesicles (MVs) to form Ag-PP@MV NPs.
🔬 The MV modification enhanced cellular uptake by macrophages and achieved an ~20% reduction of intracellular S. Typhimurium, while maintaining sustained Ag⁺ release. This demonstrates the potential of MV-coated nanoparticles for treating persistent intracellular bacterial infections
😄 Proud to note that SH-PEG-COOH (5000 Da) used in this study was purchased from Biopharma PEG Scientific Inc. (Watertown, MA, USA).
📖 Read more: https://doi.org/10.3390/ma18153470
👉 SH-PEG-COOH 5K: https://www.biochempeg.com/product/SH-PEG-COOH.html

Salmonella enterica serovar Typhimurium (S. Typhimurium) is an intracellular pathogen capable of surviving and replicating within macrophages, which causes foodborne diseases such as gastroenteritis. To develop a strategy against intracellular bacteria in macrophages, we designed silver-loaded biode...

PEG Linkers in Antibody-Drug Conjugates (ADCs)To date, 19 ADCs have been approved worldwide, and 3 of them employ PEG li...
09/11/2025

PEG Linkers in Antibody-Drug Conjugates (ADCs)

To date, 19 ADCs have been approved worldwide, and 3 of them employ PEG linkers to improve stability, solubility, and delivery:

◇ Trodelvy® (Sacituzumab govitecan) – PEGylated cleavable linker
◇ Zynlonta® (Loncastuximab tesirine) – PEG8 spacer in the linker
◇ Jiataile® (Sacituzumab tirumotecan, China) – CL2A linker incorporating PEG8

PEG linkers play a critical role in ADC design by enhancing pharmacokinetics, reducing aggregation, and enabling higher DARs.

At Biopharma PEG, we provide high-purity PEG linkers (impurities

🚀 PROTAC Therapies: From Concept to Late-Stage Clinical RealityProteolysis-targeting chimeras (PROTACs) are transforming...
08/18/2025

🚀 PROTAC Therapies: From Concept to Late-Stage Clinical Reality

Proteolysis-targeting chimeras (PROTACs) are transforming the drug development landscape. While no PROTAC-based therapies have yet reached the market, the field is rapidly advancing:

🔬 40+ PROTAC drug candidates are now in clinical trials.
🎯 Targets include AR, ER, BTK, and IRAK4.
🩺 Applications span hematological cancers, solid tumors, and autoimmune disorders.

Notably, three PROTACs have advanced to Phase 3 trials:

√ ARV-471 (Vepdegestrant) – Arvinas/Pfizer (ER degrader) → NDA accepted by FDA, PDUFA: June 5, 2026
√ BMS-986365 – Bristol Myers Squibb (AR degrader)
√ BGB-16673 – BeiGene (BTK degrader)

🌟 With multiple late-stage programs and broad therapeutic potential, PROTACs are on the brink of becoming a new drug class in modern medicine.

👉 Do you think the first FDA-approved PROTAC will arrive by 2026?
https://www.biochempeg.com/article/434.html

🔹 Y-shape-PEG-NHS, also known as 2-Arm PEG-NHS, this branched PEG derivative features NHS esters at the end of each arm—...
07/30/2025

🔹 Y-shape-PEG-NHS, also known as 2-Arm PEG-NHS, this branched PEG derivative features NHS esters at the end of each arm—perfect for efficient, targeted conjugation to amine groups on proteins, peptides, or other biomolecules.
Its unique Y-shaped design enables:
✅ Strong, stable amide bond formation
✅ Enhanced crosslinking for hydrogel networks
✅ Applications in tissue engineering & controlled drug release
At Biopharma PEG, we provide high-purity PEG derivatives—from lab-scale to commercial batches—designed to support your R&D success.
📩 Let’s talk: sales@biochempeg.com

Address

108 Water Street, Room 4D, Watertown
Watertown, MA
02472

Opening Hours

Monday 9am - 5:30pm
Tuesday 9am - 5:30pm
Wednesday 9am - 5:30pm
Thursday 9am - 5:30pm
Friday 9am - 5:30pm

Telephone

+18573666766

Alerts

Be the first to know and let us send you an email when Biopharma PEG Scientific Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Biopharma PEG Scientific Inc.:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram